ETON Earnings Prediction
The chart below shows how ETON performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ETON sees a -1.14% change in stock price 10 days leading up to the earnings, and a +8.62% change 10 days following the report. On the earnings day itself, the stock moves by -0.56%. This data can give you a slight idea of what to expect for the next quarter's release.
ETON Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.32M
46.90%
13.78%
Gross Margin
61.04%
-2.57%
-1.55%
Operating Margin
4.93%
163.21%
-115.24%
Net Margin
6.07%
173.67%
-118.11%
EPS
0.02
200.00%
-116.67%
No Data Available
ETON Earnings Analysis
Eton Pharmaceutcials, Inc. Common Stock Corporation (ETON.O) Earnings Conference Call
Positive
Product Sales Surge: Product sales were up 40% year-over-year, driven by strong increases in both ALKINDI SPRINKLE and Carglumic Acid.
FDA Review Milestone: The third quarter brought a critical milestone for our important pipeline product, ET-400, which was accepted for review by the FDA and assigned a February 28 PDUFA date.
Positive GAAP Net Income: We achieved positive GAAP net income in the third quarter, reaching our goal a quarter ahead of schedule.
Net Income Improvement: Total company net income was $0.6 million for the quarter compared to a net loss of $0.6 million in the prior year period.
Cash Position and Flow: Eton finished the third quarter with $20.3 million of cash on hand and generated $2.9 million of operating cash flow during the quarter.
Negative
Net Income Improvement: Total company net income was $0.6 million for the quarter compared to a net loss of $0.6 million in the prior year period.
Increased Administrative Expenses: General and administrative expenses for the quarter were $5.3 million compared with $4.3 million in the prior year period, due primarily to increased sales and marketing activities, legal expenses and employee-related expenses.
R&D Expense Comparison: R&D expenses for the quarter were $0.5 million compared with $0.6 million in the prior year period as overall development activities were relatively flat year-over-year.
Third Quarter Sales Surge: Net product sales for the third quarter of 2024 increased 40% to $9.8 million compared to $7.0 million in the prior year period, primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid.
Revenue Increase Analysis: Total company revenue was $10.3 million compared to $7.0 million in the third quarter of 2023.
ETON FAQs
How does ETON typically perform around its earnings report dates?
Is Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ETON Earning Call Sentiment
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ETON.O
-1.12%Positive
Eton Pharmaceuticals shows strong financial growth, achieving positive net income and a significant increase in revenue. The anticipated launch of ET-400 and acquisition of Increlex are promising, with management confident in regulatory outcomes and growth strategies. While there are risks, such as regulatory and competitive pressures, the company's proactive approach in market education and product promotion is reassuring. The Q&A section reflects optimism, despite some vagueness in responses. Overall, the positive financials, optimistic guidance, and strategic initiatives suggest a positive stock price movement.
